119 related articles for article (PubMed ID: 37424492)
1. Differences in apparent diffusion coefficient histogram analysis according to EGFR mutation status in brain metastasis due to lung adenocarcinoma.
Bilgin EY; Ünal Ö; Göç MF; Bahsi T
J Xray Sci Technol; 2023; 31(5):1035-1045. PubMed ID: 37424492
[TBL] [Abstract][Full Text] [Related]
2. MRI features and whole-lesion apparent diffusion coefficient histogram analysis of brain metastasis from non-small cell lung cancer for differentiating epidermal growth factor receptor mutation status.
Zheng Y; Huang WJ; Han N; Jiang YL; Ma LY; Zhang J
Clin Radiol; 2023 Mar; 78(3):e243-e250. PubMed ID: 36577557
[TBL] [Abstract][Full Text] [Related]
3. CT imaging-based histogram features for prediction of EGFR mutation status of bone metastases in patients with primary lung adenocarcinoma.
Shen TX; Liu L; Li WH; Fu P; Xu K; Jiang YQ; Pan F; Guo Y; Zhang MC
Cancer Imaging; 2019 Jun; 19(1):34. PubMed ID: 31174617
[TBL] [Abstract][Full Text] [Related]
4. The Utility and Efficiency of Diffusion Tensor Imaging Values to Determine Epidermal Growth Factor Receptor Gene Mutation Status in Brain Metastasis from Lung Adenocarcinoma; A Preliminary Study.
Gultekin MA; Turk HM; Yurtsever I; Atasoy B; Aliyev A; Yilmaz TF; Alkan A
Curr Med Imaging; 2020; 16(10):1271-1277. PubMed ID: 33461445
[TBL] [Abstract][Full Text] [Related]
5. Diffusion-Weighted Imaging of Brain Metastasis from Lung Cancer: Correlation of MRI Parameters with the Histologic Type and Gene Mutation Status.
Jung WS; Park CH; Hong CK; Suh SH; Ahn SJ
AJNR Am J Neuroradiol; 2018 Feb; 39(2):273-279. PubMed ID: 29301782
[TBL] [Abstract][Full Text] [Related]
6. Whole-tumor histogram analysis of multi-parametric MRI for differentiating brain metastases histological subtypes in lung cancers: relationship with the Ki-67 proliferation index.
Zhang B; Zhou F; Zhou Q; Xue C; Ke X; Zhang P; Han T; Deng L; Jing M; Zhou J
Neurosurg Rev; 2023 Sep; 46(1):218. PubMed ID: 37659040
[TBL] [Abstract][Full Text] [Related]
7. Distinguishing EGFR mutation molecular subtypes based on MRI radiomics features of lung adenocarcinoma brain metastases.
Xu J; Yang Y; Gao Z; Song T; Ma Y; Yu X; Shi C
Clin Neurol Neurosurg; 2024 May; 240():108258. PubMed ID: 38552362
[TBL] [Abstract][Full Text] [Related]
8. Lung adenocarcinoma: Assessment of epidermal growth factor receptor mutation status based on extended models of diffusion-weighted image.
Yuan M; Pu XH; Xu XQ; Zhang YD; Zhong Y; Li H; Wu JF; Yu TF
J Magn Reson Imaging; 2017 Jul; 46(1):281-289. PubMed ID: 28054731
[TBL] [Abstract][Full Text] [Related]
9. Histogram Analysis of ADC Maps for Differentiating Brain Metastases From Different Histological Types of Lung Cancers.
Bozdağ M; Er A; Çinkooğlu A
Can Assoc Radiol J; 2021 May; 72(2):271-278. PubMed ID: 32602365
[TBL] [Abstract][Full Text] [Related]
10. Diffusion kurtosis imaging: correlation analysis of quantitative model parameters with molecular features in advanced lung adenocarcinoma.
Peng Q; Tang W; Huang Y; Wu N; Yang L; Li N
Chin Med J (Engl); 2020 Oct; 133(20):2403-2409. PubMed ID: 32960838
[TBL] [Abstract][Full Text] [Related]
11. Differentiation of brain metastases originating from lung and breast cancers using apparent diffusion coefficient histogram analysis and the relation of histogram parameters with Ki-67.
Bozdağ M; Er A; Ekmekçi S
Neuroradiol J; 2022 Jun; 35(3):370-377. PubMed ID: 34609916
[TBL] [Abstract][Full Text] [Related]
12. Non-small cell lung cancer: Whole-lesion histogram analysis of the apparent diffusion coefficient for assessment of tumor grade, lymphovascular invasion and pleural invasion.
Tsuchiya N; Doai M; Usuda K; Uramoto H; Tonami H
PLoS One; 2017; 12(2):e0172433. PubMed ID: 28207858
[TBL] [Abstract][Full Text] [Related]
13. Effects of different brain surveillance strategies on outcomes for patients with EGFR-mutant metastatic lung adenocarcinoma under targeted therapy.
Shen CI; Huang HC; Chiang CL; Luo YH; Shiao TH; Chiu CH
Lung Cancer; 2019 Dec; 138():52-57. PubMed ID: 31634655
[TBL] [Abstract][Full Text] [Related]
14. Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score.
Lee DW; Shin DY; Kim JW; Keam B; Kim TM; Kim HJ; Kim DW; Wu HG; Paek SH; Kim YW; Heo DS; Kim DG; Lee SH
Lung Cancer; 2014 Dec; 86(3):363-8. PubMed ID: 25453849
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of the systemic immune-inflammation index in brain metastases from lung adenocarcinoma with different EGFR mutations.
Li H; Wang G; Zhang H; Song X; Cao J; Zhang X; Xue R; Wang W; Jia S; Li Z
Genes Immun; 2019 Jul; 20(6):455-461. PubMed ID: 30410015
[TBL] [Abstract][Full Text] [Related]
16. Multiparametric MRI-Based Radiomics Approaches for Preoperative Prediction of EGFR Mutation Status in Spinal Bone Metastases in Patients with Lung Adenocarcinoma.
Jiang X; Ren M; Shuang X; Yang H; Shi D; Lai Q; Dong Y
J Magn Reson Imaging; 2021 Aug; 54(2):497-507. PubMed ID: 33638577
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of intratumor metabolic and heterogeneity parameters on [
Ni M; Wang S; Liu X; Shi Q; Zhu X; Zhang Y; Xie Q; Lv W
Jpn J Radiol; 2023 Feb; 41(2):209-218. PubMed ID: 36219311
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival.
Joo JW; Hong MH; Shim HS
Lung Cancer; 2018 Jul; 121():12-17. PubMed ID: 29858020
[TBL] [Abstract][Full Text] [Related]
19. Development of Brain Metastases in Patients With Non-Small Cell Lung Cancer and No Brain Metastases at Initial Staging Evaluation: Cumulative Incidence and Risk Factor Analysis.
Kim M; Suh CH; Lee SM; Park JE; Kim HC; Kim SO; Aizer AA; Yanagihara TK; Bai HX; Guenette JP; Huang RY; Kim HS
AJR Am J Roentgenol; 2021 Nov; 217(5):1184-1193. PubMed ID: 34037408
[No Abstract] [Full Text] [Related]
20. Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Jain A; Lim C; Gan EM; Ng DZ; Ng QS; Ang MK; Takano A; Chan KS; Tan WM; Kanesvaran R; Toh CK; Loo CM; Hsu AA; Devanand A; Lim CH; Koong HN; Koh T; Fong KW; Yap SP; Kim SW; Chowbay B; Oon L; Lim KH; Lim WT; Tan EH; Tan DS
PLoS One; 2015; 10(5):e0123587. PubMed ID: 25955322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
